Elanco Animal Health has been granted a patent for interleukin 13 receptor subunit alpha-1/interleukin 4 receptor subunit alpha (IL13R/IL4R) polypeptides for treating IL13 and/or IL4-induced conditions in companion animals. The polypeptides are derived from canines, felines, and equines, with sequences closely matching specific IDs. GlobalData’s report on Elanco Animal Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Elanco Animal Health Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Elanco Animal Health, NSAID cancer drugs was a key innovation area identified from patents. Elanco Animal Health's grant share as of April 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Polypeptides for treating il13 and il4-induced conditions in animals

Source: United States Patent and Trademark Office (USPTO). Credit: Elanco Animal Health Inc

A recently granted patent (Publication Number: US11970526B2) discloses a polypeptide with specific amino acid sequences closely related to sequences identified as SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 21, 28, 29, 30, and 31. The polypeptide may also include post-expression modifications such as glycosylation, sialyation, acetylation, or phosphorylation. Furthermore, the patent claims that the polypeptide can bind to IL13 and IL4 of companion animal species with a dissociation constant (Kd) of less than 5×10-6 M, as measured by biolayer interferometry.

Moreover, the patent includes claims for pharmaceutical compositions containing the polypeptide in combination with a pharmaceutically acceptable carrier. These compositions can be in solid or liquid form, providing potential applications in the development of therapeutic treatments for conditions related to IL13 and IL4 binding in companion animal species. The patent emphasizes the importance of the specific amino acid sequences and post-expression modifications in enhancing the binding capabilities of the polypeptide to the target proteins, highlighting the potential for novel pharmaceutical interventions in veterinary medicine.

To know more about GlobalData’s detailed insights on Elanco Animal Health, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies